Skip to Main Content

By most measures, biotech investors shouldn’t have too many gripes about the first half of 2017. The go-go years of 2013 and 2014 aren’t making a roaring comeback, but our little corner of Wall Street has outperformed the broader market despite the constant threat of D.C. meddling. As the July Fourth holiday approaches, biotech investors can pause, crack open a can of their favorite hoppy IPA, and consider the stock-moving events and story lines that will make or break the back half of 2017.

The following are my picks for the most important events on the docket. STAT Plus subscribers, please weigh in with your selections (or ask about mine) during an exclusive, live online chat with me at 2 pm EDT. Come back to this story a few minutes before 2 to log in and join the conversation.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

  • Very disappointed to see today’s article by Adam Feurstein. He has published biased and inaccurate reports on companies in the past. A case in point was his report on a Phase 2 trial by Corbus Pharma (CRBP). He was critical of Corbus’ claiming a lack of efficacy of their drug candidate resunab despite the fact that Corbus made it very clear that the purpose was safety and tolerability and the trial was not powered to prove efficacy. Incidentally, Corbus was the number one small biotech for growth in 2016.

Comments are closed.